Noninvasive VNS to Facilitate Excitability in Motor Cortex

NCT ID: NCT04130646

Last Updated: 2025-04-20

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-15

Study Completion Date

2024-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Transcranial Magnetic Stimulation (TMS) positively influences motor rehabilitation in stroke recovery. Transcutaneous auricular vagus nerve stimulation (taVNS) has shown effects on cortical plasticity. We investigate whether combination of TMS and taVNS is more effective at motor cortex excitability than either modality alone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators aim to determine the effects of taVNS on motor cortex excitability. The hypothesis is that taVNS alone (sham rTMS + active taVNS) will induce increases in motor cortex excitability (post-stimulation compared to baseline). The investigators expect these changes will be of a lesser magnitude than those of TMS alone (active rTMS + sham taVNS) due to the indirect mechanistic approach of taVNS. Another aim is to determine whether taVNS-paired TMS is more effective at inducing cortical excitability than TMS alone, as it is hypothesized that pairing two forms of neuromodulation (active rTMS + active taVNS) will increase TMS-induced cortical excitability in the motor cortex when compared to single modality approaches (active rTMS + sham taVNS; sham rTMS + active taVNS). Furthermore, it is expected that this increase is timing sensitive, and the paired approach will induce larger TMS-induced cortical excitability compared to unpaired neuromodulation (active taVNS + active taVNS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Stroke Sequelae Motor Activity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TMS combined with taVNS

Group Type EXPERIMENTAL

Transcranial Magnetic Stimulation

Intervention Type DEVICE

transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull

transcutaneous auricular vagus nerve stimulation (taVNS)

Intervention Type DEVICE

non-invasive vagus nerve stimulation delivers electricity to the ear

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Magnetic Stimulation

transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull

Intervention Type DEVICE

transcutaneous auricular vagus nerve stimulation (taVNS)

non-invasive vagus nerve stimulation delivers electricity to the ear

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-80
* endorsing good health

Exclusion Criteria

* no TMS-induced motor cortex excitability changes in response to 20Hz motor cortex rTMS
* active psychiatric or neurological disorders
* history of CNS disease, concussion, overnight hospitalization, or other neurologic sequelae, tumors, seizures, frequent or severe headaches
* metal implanted above the neck
* currently taking seizure reducing medications
* currently taking psychotropic medications
* any psychotropic medication taken within 5 half-lives of procedure time
* abuse or dependence of drugs (excluding nicotine and caffeine)
* currently taking medications that lower the seizure threshold
* taking any of the stimulants, thyroid medication, or steroids
* implanted devices/ferrous metal of any kind
* history of seizure or seizure disorder
* inability to determine motor threshold.
* Pregnant females and children under the age of 18 will be excluded for safety reasons
* No vulnerable populations or special classes of subjects will be considered for participation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of South Carolina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

00089851

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Combined tDCS+PNS After Acute Stroke
NCT01207336 COMPLETED PHASE2/PHASE3